Two New Biotechs Spin Out From Edinburgh’s Regenerative Medicine Centre
Separate Investments From Syncona and SV Health Investors
Scotland’s investment in regenerative medicine is paying off with two promising start-ups, one targeting liver disease, the other oncology, launching within days of each other.
You may also be interested in...
The UK’s biotech sector sees investor interest surge during the pandemic, though IPO levels are still disappointing compared with recent years.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.